Skip Nav Destination
Issues
1 March 2012
-
Cover Image
Cover Image
Anchorage-independent growth in semisolid medium and the formation of xenografts in immunocompromised mice are generally considered to be informative for assessing human cell tumorigenicity. Long-term treatment with cigarette smoke condensate (CSC) significantly increases (versus DMSO control or no treatment) the anchorage-independent growth of A549 lung adenocarcinoma cells. A549 cells were treated with CSC for 300 days (mimicking long-term cigarette smoking) and were allowed to grow for 14 days in soft agarose. The cover features a phase-contrast micropictogram (40× magnification) of colonies of these cells that do not require a solid substratum for growth, an important characteristic feature of cancer cells. 300-Day CSC treated cells were injected s.c. into athymic nude mice, producing tumors of significantly increased volume (P < 0.001) and rate of development (P < 0.01) at 12 weeks [versus injected 300-day DMSO or parental (no-treatment) cells, not shown]. These oncogenic effects were due partly to down-regulation of Smad3. Immortalized bronchial epithelial HPL1A cells, however, did not exhibit similar phenotypes, putatively because these cells may require a longer period of CSC treatment to undergo the additional genetic or epigenetic changes necessary to become tumorigenic. See article by Samanta et al. (beginning on page 453) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Perspective
Research Articles
Metformin Inhibits Cell Proliferation, Migration and Invasion by Attenuating CSC Function Mediated by Deregulating miRNAs in Pancreatic Cancer Cells
Bin Bao; Zhiwei Wang; Shadan Ali; Aamir Ahmad; Asfar S. Azmi; Sanila H. Sarkar; Sanjeev Banerjee; Dejuan Kong; Yiwei Li; Shivam Thakur; Fazlul H. Sarkar
Genetic Variants Associated with the Risk of Chronic Obstructive Pulmonary Disease with and without Lung Cancer
Mariza de Andrade; Yan Li; Randolph S. Marks; Claude Deschamps; Paul D. Scanlon; Curtis L. Olswold; Ruoxiang Jiang; Stephen J. Swensen; Zhifu Sun; Julie M. Cunningham; Jason A. Wampfler; Andrew H. Limper; David E. Midthun; Ping Yang
Functional Protein Pathway Activation Mapping of the Progression of Normal Skin to Squamous Cell Carcinoma
Janine G. Einspahr; Valerie Calvert; David S. Alberts; Clara Curiel-Lewandrowski; James Warneke; Robert Krouse; Steven P. Stratton; Lance Liotta; Caterina Longo; Giovanni Pellicani; Anil Prasad; Paul Sagerman; Yira Bermudez; Jianghong Deng; G. Timothy Bowden; Emanuel F. Petricoin, III
Uterine Serous Carcinoma: Increased Familial Risk for Lynch-Associated Malignancies
Summer B. Dewdney; Nora T. Kizer; Abegail A. Andaya; Sheri A. Babb; Jingqin Luo; David G. Mutch; Amy P. Schmidt; Louise A. Brinton; Russell R. Broaddus; Nilsa C. Ramirez; Phyllis C. Huettner; Donald Scott McMeekin; Kathleen Darcy; Shamshad Ali; Patricia L. Judson; Robert S. Mannel; Shashikant B. Lele; David M. O'Malley; Paul J. Goodfellow
DNA Methylation of Phosphatase and Actin Regulator 3 Detects Colorectal Cancer in Stool and Complements FIT
Linda J.W. Bosch; Frank A. Oort; Maarten Neerincx; Carolina A.J. Khalid-de Bakker; Jochim S. Terhaar sive Droste; Veerle Melotte; Daisy M.A.E. Jonkers; Ad A.M. Masclee; Sandra Mongera; Madeleine Grooteclaes; Joost Louwagie; Wim van Criekinge; Veerle M.H. Coupé; Chris J. Mulder; Manon van Engeland; Beatriz Carvalho; Gerrit A. Meijer
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.